Eli Lilly may drop inhaled insulin plan

Eli Lilly and Co. has pulled the plug on a collaboration with a Massachusetts company to develop inhaled insulin for diabetics.

Alkermes Inc. said it received a letter Friday from Lilly terminating the development and license agreement for AIR Inhaled Insulin. The announcement was made shortly after Alkermes released a statement that Lilly was evaluating its business case for the drug.

AIR Insulin is being evaluated in a broad phase-3 clinical trial program with patients with type 1 and type 2 diabetes. Alkermes said it was not aware of any safety, efficacy or manufacturing issues that would lead to the termination of the agreement.

Copyright 2008 by United Press International


Explore further

Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?

Citation: Eli Lilly may drop inhaled insulin plan (2008, March 10) retrieved 27 January 2022 from https://medicalxpress.com/news/2008-03-eli-lilly-inhaled-insulin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors